JP2012500389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500389A5 JP2012500389A5 JP2011523144A JP2011523144A JP2012500389A5 JP 2012500389 A5 JP2012500389 A5 JP 2012500389A5 JP 2011523144 A JP2011523144 A JP 2011523144A JP 2011523144 A JP2011523144 A JP 2011523144A JP 2012500389 A5 JP2012500389 A5 JP 2012500389A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- gene product
- multiple myeloma
- marker
- mirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091070501 miRNA Proteins 0.000 claims 39
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 239000000047 product Substances 0.000 claims 28
- 238000000034 method Methods 0.000 claims 24
- 108091050874 miR-19a stem-loop Proteins 0.000 claims 19
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 claims 19
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 claims 19
- 108091037787 miR-19b stem-loop Proteins 0.000 claims 19
- 201000000050 myeloid neoplasm Diseases 0.000 claims 19
- 108091024082 miR-32 stem-loop Proteins 0.000 claims 14
- 238000012360 testing method Methods 0.000 claims 13
- 239000003550 marker Substances 0.000 claims 11
- 208000034578 Multiple myelomas Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000002679 microRNA Substances 0.000 claims 9
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 claims 8
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 7
- 230000004075 alteration Effects 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000009396 hybridization Methods 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims 1
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229940124660 anti-multiple myeloma Drugs 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001632 homeopathic effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000037353 metabolic pathway Effects 0.000 claims 1
- 108091091751 miR-17 stem-loop Proteins 0.000 claims 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 claims 1
- 108091074848 miR-19 stem-loop Proteins 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8803608P | 2008-08-12 | 2008-08-12 | |
| US61/088,036 | 2008-08-12 | ||
| PCT/US2009/053586 WO2010019694A1 (en) | 2008-08-12 | 2009-08-12 | Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500389A JP2012500389A (ja) | 2012-01-05 |
| JP2012500389A5 true JP2012500389A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-09-13 |
Family
ID=41669274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523144A Pending JP2012500389A (ja) | 2008-08-12 | 2009-08-12 | 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法 |
Country Status (7)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103820562B (zh) | 2005-08-01 | 2015-05-13 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
| WO2007033023A2 (en) | 2005-09-12 | 2007-03-22 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of bcl2-associated cancers |
| WO2007081680A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| EP2487258B1 (en) | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer |
| CA2633674A1 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| EP1996731A2 (en) | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
| EP2436783B1 (en) | 2006-07-13 | 2013-09-11 | The Ohio State University Research Foundation | MIR-103-2 for diagnosing poor survival prognosis colon adenocarcinoma. |
| WO2008097277A2 (en) | 2006-09-19 | 2008-08-14 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
| CA2667617A1 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CA2674895A1 (en) | 2007-01-31 | 2008-08-07 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml) |
| CN101711287B (zh) | 2007-06-08 | 2016-04-27 | 由卫生与公众服务部代表的美利坚合众国政府 | 确定肝细胞癌亚型和检测肝癌干细胞的方法 |
| EP2167521A4 (en) | 2007-06-15 | 2011-11-23 | Univ Ohio State Res Found | ONKOGEN ALL-1 FUSION PROTEINS FOR TARGETING DROSHA-MEDIATED microRNA PROCESSING |
| ES2496172T3 (es) | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| ES2627059T3 (es) | 2007-08-03 | 2017-07-26 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
| WO2009026487A1 (en) | 2007-08-22 | 2009-02-26 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| CN102137927B (zh) | 2007-10-26 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
| AU2009257410B2 (en) | 2008-06-11 | 2014-03-06 | Fudan University | Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
| CA2781547A1 (en) | 2009-11-23 | 2011-05-26 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| CN102241773B (zh) * | 2010-05-13 | 2014-05-14 | 四川大学 | 抗骨髓瘤细胞多克隆抗体及其制备方法 |
| ES2606146T3 (es) | 2010-11-12 | 2017-03-22 | The Ohio State University Research Foundation | Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal |
| AU2011329066B2 (en) | 2010-11-15 | 2017-03-09 | The Ohio State University Research Foundation | Controlled release mucoadhesive systems |
| GB2486424A (en) * | 2010-12-13 | 2012-06-20 | Univ Sussex | Markers for plasma cell disorders |
| US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
| US8945829B2 (en) * | 2011-03-22 | 2015-02-03 | Cornell University | Distinguishing benign and malignant indeterminate thyroid lesions |
| WO2012129378A1 (en) * | 2011-03-22 | 2012-09-27 | Keutgen Xavier M | Distinguishing benign and malignant indeterminate thyroid lesions |
| JP2014530612A (ja) | 2011-10-14 | 2014-11-20 | ジ・オハイオ・ステート・ユニバーシティ | 卵巣がんに関する方法および材料 |
| JP6441679B2 (ja) | 2011-12-09 | 2018-12-19 | メタベンション インコーポレイテッド | 肝臓系の治療的な神経調節 |
| WO2013090556A1 (en) | 2011-12-13 | 2013-06-20 | The Ohio State University | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| WO2013110053A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| EP2885425B1 (en) | 2012-08-20 | 2017-07-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Expression of protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer |
| WO2014071205A1 (en) * | 2012-11-02 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies |
| KR20180088690A (ko) * | 2015-12-03 | 2018-08-06 | 알프레드 헬스 | 골수종의 치료 또는 진행의 모니터링 |
| CN105603087B (zh) * | 2016-02-01 | 2019-03-01 | 中国医学科学院血液病医院（血液学研究所） | 检测多发性骨髓瘤克隆进化的基因探针组合物及试剂盒 |
| CN107847515B (zh) * | 2016-07-06 | 2021-01-29 | 优美佳生物技术有限公司 | 实体瘤甲基化标志物及其用途 |
| CN110223733B (zh) * | 2019-04-22 | 2022-02-01 | 福建医科大学附属第一医院 | 一种多发性骨髓瘤预后基因的筛查方法 |
| WO2020226960A1 (en) * | 2019-05-03 | 2020-11-12 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| US20210002698A1 (en) * | 2019-07-02 | 2021-01-07 | Quark Biosciences Taiwan, Inc. | miRNA Receptivity Analysis of the Endometrium |
| CN110564852A (zh) * | 2019-08-06 | 2019-12-13 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 与人类多发性骨髓瘤相关的miRNAs表达图谱模型、构建方法及应用 |
| CN113186163A (zh) * | 2021-01-18 | 2021-07-30 | 南昌五元生物科技有限公司 | 一种基于p53突变筛选肿瘤类器官的培养方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1713938A2 (en) * | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| EP2290068A3 (en) * | 2004-05-28 | 2012-01-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP2284265B1 (en) * | 2004-11-12 | 2015-01-07 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| JP2008539731A (ja) * | 2005-05-02 | 2008-11-20 | コールド スプリング ハーバー ラボラトリー | 癌の診断及び治療のための組成物及び方法 |
| EP1996731A2 (en) * | 2006-03-20 | 2008-12-03 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
| EP2436783B1 (en) * | 2006-07-13 | 2013-09-11 | The Ohio State University Research Foundation | MIR-103-2 for diagnosing poor survival prognosis colon adenocarcinoma. |
| EP2145001A2 (en) * | 2006-09-19 | 2010-01-20 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| CA2699418A1 (en) * | 2007-02-27 | 2008-09-04 | Moshe Oren | Composition and methods for modulating cell proliferation and cell death |
| US8097427B2 (en) * | 2007-03-16 | 2012-01-17 | Covalx Ag | Direct mass spectrometric analysis of drug candidates targeting protein complexes |
| CN102084000B (zh) * | 2008-02-01 | 2016-03-16 | 总医院有限公司 | 微泡在医学疾病和病况的诊断、预后以及治疗中的用途 |
-
2009
- 2009-08-12 CN CN2009801354566A patent/CN102149401A/zh active Pending
- 2009-08-12 EP EP09807241A patent/EP2323677A4/en not_active Withdrawn
- 2009-08-12 WO PCT/US2009/053586 patent/WO2010019694A1/en active Application Filing
- 2009-08-12 AU AU2009281969A patent/AU2009281969A1/en not_active Abandoned
- 2009-08-12 JP JP2011523144A patent/JP2012500389A/ja active Pending
- 2009-08-12 CA CA2734179A patent/CA2734179A1/en not_active Abandoned
- 2009-08-12 US US13/058,662 patent/US20110152357A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500389A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP7186700B2 (ja) | 腫瘍抑制ｆｏｘｏ活性を酸化ストレスから区別する方法 | |
| JP2009543552A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2011500071A (ja) | 遺伝子に基づくアルゴリズム的ガン予後及び患者の臨床結果 | |
| US20130252837A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
| JP2010535473A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Loftus et al. | Hypoxia‐induced HIF 1α targets in melanocytes reveal a molecular profile associated with poor melanoma prognosis | |
| KR20120065959A (ko) | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 | |
| JP2011517932A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2018078911A (ja) | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 | |
| BR122020016370B1 (pt) | métodos para predizer um resultado de câncer de mama em um tumor de mama positivo para receptor de estrogênio e negativo para her2 de um paciente com câncer de mama | |
| CN106662543B (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| WO2013052480A1 (en) | Marker-based prognostic risk score in colon cancer | |
| JP6546248B2 (ja) | ｍｉＲＮＡの発現を分析することによって大腸癌の転帰を予測するための方法 | |
| CA3109391A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
| CN103608683A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| CA2660857A1 (en) | Prognostic and diagnostic method for disease therapy | |
| CA2859021A1 (en) | Methods and kits for detecting subjects at risk of having cancer | |
| JP2008512984A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma | |
| EP3144395A1 (en) | Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer | |
| US20120095030A1 (en) | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors | |
| CN109781985A (zh) | 用于检测癌症放疗敏感性的试剂盒及其应用 | |
| CN102027131A (zh) | 癌症分期与治疗的系统和方法 | |
| Wang et al. | Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas |